Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Greystoke, Alastair
Oughton, Jamie B.
Brown, Sarah R.
Butterworth, Karl
Coyle, Victoria
Franks, Kevin
Hassani, Adam
Harrow, Stephen
Hatton, Matthew
Hiley, Crispin T.
Kendall, Jessica
Phillip, Rachel
Norris, Matthew
Ojo, Oluwaseun
Shaw, Paul
Walker, Fiona
Yang, Huiqi
Chalmers, Anthony J.
Faivre-Finn, Corinne
机构：
[1] Univ Newcastle, Northern Ctr Canc Care, Newcastle Upon Tyne, England
[2] Univ Leeds, Leeds Inst Clin Trials Res, Leeds, England
[3] Queens Univ Belfast, Belfast, North Ireland
[4] Leeds Teaching Hosp NHS Trust, Leeds, England
[5] Northern Ctr Canc Care, Newcastle Upon Tyne, England
[6] Edinburgh Canc Ctr, Western Gen Hosp, Edinburgh, Scotland
[7] Weston Pk Hosp, Sheffield, England
[8] Univ Coll Hosp London, London, England
[9] AstraZeneca, Cambridge, England
[10] Velindre Canc Ctr, Cardiff, Wales
[11] Cambridge Univ Hosp, Cambridge, England
[12] Univ Glasgow, Glasgow, Scotland
[13] Christie NHS Fdn Trust, Manchester, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8119
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PHASE IB STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF OLAPARIB (AZD2281) PLUS GEFITINIB IN PATIENTS (P) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (P). (NCT=1513174/GECP-GOAL)
    Garcia Campelo, Rosario
    Felip, Enriqueta
    Massuti, Bartomeu
    Majem, Margarita
    Carcereny, Enric
    Palmero, Ramon
    Angel Molina-Vila, Miguel
    Cajal, Rosana
    Sanchez-Ronco, Maria
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S914 - S914
  • [42] A phase II study of 3 sequence-dependent docetaxel (D)/vinorelbine(V) DNA damage-induced apoptosis in patients with non-small cell lung cancer (NSCLC)
    Balañá, C
    Martín, C
    Rosell, R
    Monzó, M
    Manzano, JL
    Guillot, M
    Font, K
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S66 - S66
  • [43] Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC)
    Camidge, D. R.
    Conkling, P.
    Stephenson, J. J.
    Glassman, P. M.
    Zhao, Y.
    Kaiser, R.
    Stopfer, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] A single-arm phase Ib study of multiple target cytotoxic T-lymphocyte (MCTL) in combination with toripalimab as second-line therapy in advanced non-small cell lung cancer (NSCLC).
    Ren, Xiubao
    Zhang, Weihong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.
    Mamdani, Hirva
    Clarke, Jeffrey Melson
    Gu, Lin
    Stinchcombe, Tom
    Crawford, Jeffrey
    Antonia, Scott Joseph
    Campa, Michael
    Nixon, Andrew B.
    Sonpavde, Guru P.
    Simon, George R.
    Ready, Neal E.
    Herndon, James E., II
    Patz, Edward F.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Concurrent chemo-radiotherapy with docetaxel-cisplatin followed by docetaxel consolidation therapy in inoperable stage IIIA/B non-small cell lung cancer (NSCLC): updated results of a Phase I study
    Huber, Rudoif M.
    Borgmeier, Astrid
    Flentje, Michael
    Willner, Jochen
    Schmidt, Michael
    Manegold, Christian
    Debus, Juergen
    ANNALS OF ONCOLOGY, 2004, 15 : 172 - 173
  • [47] Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC).
    Papadimitrakopoulou, V
    Boasberg, P
    Figlin, R
    Zinner, R
    Blumenschein, G
    King, L
    Truong, M
    Patel, K
    Brown, GL
    Hanna, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 651S - 651S
  • [48] Phase II study of low-dose paclitaxel with timed thoracic radiotherapy (TTR) followed by gemcitabine and carboplatin consolidation in patients with unresectable stage III non-small cell lung cancer (NSCLC): NCT 00449657
    Zhang, J.
    Russo, S. M.
    Gay, H. A.
    Parent, T.
    Nelson, Z.
    Eubanks, S.
    Walker, P. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).
    Besse, B.
    Soria, J.
    Gomez-Roca, C.
    Ware, J. A.
    Adjei, A. A.
    Dy, G. K.
    Shankar, G.
    Brachmann, R. K.
    Groen, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] A Phase Ib Study to Evaluate the P13-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
    Groen, H.
    Adjei, A. A.
    Dy, G. K.
    Ware, J. A.
    Shankar, G.
    Brachmann, R. K.
    Besse, B.
    Bahleda, R. K.
    Gomez-Roca, C.
    Soria, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S595 - S595
12345